ADC Therapeutics SA
ADCT
$3.54
-$0.41-10.38%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.35% | 15.73% | 10.49% | 1.84% | -42.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.35% | 15.73% | 10.49% | 1.84% | -42.30% |
| Cost of Revenue | -3.72% | 9.16% | -4.71% | -1.57% | -12.54% |
| Gross Profit | 35.80% | 12.65% | 46.11% | 12.49% | -235.99% |
| SG&A Expenses | -12.07% | -12.82% | -15.70% | -18.87% | -21.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.34% | -0.37% | -7.65% | -14.46% | -19.35% |
| Operating Income | 11.32% | 8.11% | 15.99% | 21.29% | -1.27% |
| Income Before Tax | 1.57% | 1.56% | 20.61% | 21.53% | 7.18% |
| Income Tax Expenses | -97.48% | -97.27% | -99.57% | -99.58% | 4,422.57% |
| Earnings from Continuing Operations | 21.31% | 20.92% | 34.07% | 34.25% | -17.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.31% | 20.92% | 34.07% | 34.25% | -17.53% |
| EBIT | 11.32% | 8.11% | 15.99% | 21.29% | -1.27% |
| EBITDA | 11.23% | 8.24% | 16.18% | 21.53% | -1.10% |
| EPS Basic | 39.57% | 38.41% | 47.48% | 43.56% | -8.08% |
| Normalized Basic EPS | 29.26% | 28.53% | 36.79% | 32.76% | 16.24% |
| EPS Diluted | 39.57% | 38.41% | 47.48% | 43.56% | -8.08% |
| Normalized Diluted EPS | 29.26% | 28.53% | 36.79% | 32.76% | 16.24% |
| Average Basic Shares Outstanding | 26.67% | 25.78% | 25.73% | 18.86% | 12.42% |
| Average Diluted Shares Outstanding | 26.67% | 25.78% | 25.73% | 18.86% | 12.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |